What you should know:
1. OM1 Inc. is developing the AI system, which recognizes clinical characteristics common with NASH patients.
2. OM1 expects the system will become “smarter” and will improve sensitivity and specificity rates as it learns from screening.
3. Testing for NASH drains physician resources. If successful, the algorithm could reduce the biopsy reliance.
4. OM1 said the algorithm could test for other diseases as well.
More articles on gastroenterology:
How total joints propelled an Ohio-based ASC’s strategy for growth and a bigger location
Fox Valley Orthopedics’ Dr. Vishal Mehta on total joint replacement
Orthopedic trauma, spine & more: 3 trends, growth areas for ASCs
